https://pubmed.ncbi.nlm.nih.gov/36300634/

J Gastroenterol Hepatol. 2022 Oct 27.
doi: 10.1111/jgh.16039. Online ahead of print.
Liver abnormalities in celiac disease and response to gluten free diet: A systematic review and meta-analysis
Anuraag Jena 1, Praveen Kumar-M 2, Antriksh Kumar 1, Chhagan Lal Birda 1, Arup Choudhury 1, Naveen Kumar 1, Daryl Ramai 3, Antonio Facciorusso 4, Jayanta Samanta 1
Affiliations expand
PMID: 36300634

DOI: 10.1111/jgh.16039
Full text linksCite
Abstract

Background: Liver involvement in celiac disease (CeD) is known but its various etiologies and the effect of gluten free diet (GFD) on it is understudied.

Methods: We searched PubMed, Medline & Embase databases from date of inception to March 7, 2022, to look for studies reporting on CeD and liver abnormalities. Pooled proportion of CeD patients with deranged transaminases, etiologies of various other liver diseases with CeD and the response to GFD were estimated. Subgroup analyses based on the age group, geographic distribution and duration of GFD were also done.

Results: Total 42 studies (8976 patients) reported hyper-transaminasemia in patients with celiac disease. The pooled proportion of patients with elevated transaminases was 21.42% (95% CI:17.02-26.59, I2 =94%) overall, with similar prevalencted among adults (21.20%) and children (21.51%). The commonest etiology was celiac hepatitis at 49.23% (95% CI:30.09-68.59, I2 =87%). Compliance with GFD was noted in 90.27%. The proportion of CeD patients with liver abnormalities who showed response to GFD was 86.39% (95% CI: 80.04-90.95, I2 =74%) overall.

Conclusion: Liver involvement was noted in 21.42 % of CeD patients. Celiac hepatitis was reported in nearly half of them. Good compliance and response were noted with GFD. (PROSPERO No.: CRD42020207354).

Published on: 
Oct-2022

CLF Intro movie

Financial Aid Offered by Trusts

Follow us on: